Floatz logo

Dp Cd8 Til

Urogenital Cancer

AgonOx, Inc.Cell therapyPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

15 Active assets in the Urogenital Cancer cohort.

Asset / SponsorPhaseRating
Nivolumab
Spanish Oncology Genito-Urinary Group
Phase 2B
Tadalafil
Regina Elena Cancer Institute
Phase 3B
Ipilimumab
Dana-Farber Cancer Institute
Phase 2B
Atezolizumab
British Columbia Cancer Agency
Phase 2B
Riluzole
University of California, Irvine
Phase 2CCC

View all 31 →

Same molecule, other indications

Dp Cd8 Til is also rated in:

head and neck squamous cell carcinomaDormant
CC
Indicative ·
41 / 100
View asset →
female reproductive organ cancerDormant
CC
Indicative ·
41 / 100
View asset →
melanomaDormant
C
Indicative ·
37 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →